Ferric derisomaltose in hospitalised and ambulatory patients with heart failure-insights from the IRONMAN trial

11 May 2024 (15:00 - 15:45)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Matthew M Y Lee

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail

Clinical management strategies of cardiologists in heart failure with reduced ejection fraction

Doctor T. Kivrak (Elazig, TR)

Abstract Slides Video

Presentation thumbnail

Prevalence, characteristics, and phenotype associated with tachycardiomyopathy in a cohort of patients first hospitalized for heart failure with reduced ejection fraction

Mr P. de la Fuente Lopez (Santiago de Compostela, ES)

Abstract Slides Video

Presentation thumbnail

An intensive nurse-led telemedicine program is effective in achieving optimized up-titration of prognostic drugs in heart failure with reduced ejection fraction patients

Mrs M. Vicente Elcano (Barcelona, ES)

Abstract Slides Video

Presentation thumbnail

Effect of initiation of sacubitril/valsartan on 24 hours blood pressure in patients with heart failure with reduced ejection fraction

Mr M. Pavelko (Lutsk, UA)

Abstract Slides Video

Presentation thumbnail

TAPSE is a small but big important detail in candidates for heart transplantation

Professor R. Acar (Istanbul, TR)

Abstract Slides Video

Access the full session

Session thumbnail

Chronic heart failure - pathophysiology and mechanisms 11

The Event

Event poster

Heart Failure 2024

11 May 2024 15:00 CET

You may be interested in

Congress Presentation

Ferric derisomaltose: IRONMAN

Congress Presentation

Reasons for hospitalisation and mode of death for patients with heart failure and iron deficiency in the IRONMAN randomized trial.

Congress Presentation

IRONMAN

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources